C
CPTx
At CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases
About CPTx
CPTx is a pioneering biotechnology company dedicated to developing innovative treatment paradigms for unmet medical challenges, with an initial focus on infectious diseases. Our mission is to revolutionize the way these conditions are treated, improving patient outcomes and addressing critical global health needs.
Read full description
At CPTx, we leverage cutting-edge science and technology to identify and advance novel therapeutic approaches. Our interdisciplinary team of scientists, researchers, and industry experts is committed to pushing the boundaries of medical innovation to create effective and accessible treatments for patients worldwide.
Our primary focus is on infectious diseases, which continue to pose significant threats to public health. By targeting these diseases, we aim to develop new therapies that can combat drug resistance, enhance treatment efficacy, and reduce the burden of infection. Our research and development efforts are guided by a deep understanding of disease mechanisms and a commitment to rigorous scientific inquiry.
CPTx's innovative approach includes the exploration of new molecular targets, the development of advanced drug delivery systems, and the application of state-of-the-art diagnostic tools. We collaborate with leading academic institutions, research organizations, and industry partners to accelerate the translation of our discoveries into clinical applications.
In addition to our focus on infectious diseases, CPTx is committed to addressing other unmet medical needs. Our platform technologies and scientific expertise enable us to explore a wide range of therapeutic areas, from rare diseases to chronic conditions. By pursuing a multi-faceted approach, we aim to create a diverse pipeline of innovative treatments that can transform patient care.
At CPTx, we are driven by a passion for improving lives and a dedication to scientific excellence. Our commitment to ethical and responsible research ensures that our solutions are developed with the well-being of patients and the broader community in mind.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Planegg, Germany
- Employees
- 49
- Open positions
- None listed
- Dealroom signal
- 84.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Infections and Infectious Diseases, Genetics and genomics, Gene Therapy, Disease, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2024 | $29M | $116M | Andrej Henkler · Bayern Kapital · Stefan Oschmann · BlueYard Capital | ↗ |
| SEED✓Equity / VC | Feb 2024 | — | — | BlueYard Capital | — |
Growth signals
Latest recorded traffic for CPTx is 2.6K monthly website visits, up 160% over the last three months. CPTx's team grew 14% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
BlueYard Capital
Series A4 investors entered at this stage
SPRIN-D
Andrej Henkler
Bayern Kapital
Stefan Oschmann
Other known investors1 additional known investor
Leblon Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CPTx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CPTx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







